Lus Giacomo, Cantello Roberto, Danni Maura Chiara, Rini Agusto, Sarchielli Paola, Tassinari Tiziana, Signoriello Elisabetta
Multiple Sclerosis Center, II Division of Neurology, Department of Clinical & Experimental Medicine, Second University of Naples, Naples, Italy.
Department of Neurology, University of Eastern Piedmont, Novara, Italy.
Neurodegener Dis Manag. 2018 Apr;8(2):105-113. doi: 10.2217/nmt-2017-0056. Epub 2018 Apr 23.
Complaints about Δ-tetrahydrocannabinol (THC):cannabidiol (CBD) oromucosal spray (Sativex; GW Pharma Ltd, Salisbury, UK) in the management of multiple sclerosis spasticity include unpleasant taste and oral mucosal anomalies. This pilot study assessed the use of sugar-free chewing gum and/or a refrigerated bottle of THC:CBD oromucosal spray to mitigate these effects.
MATERIALS & METHODS: Patients with multiple sclerosis spasticity (n = 52) at six sites in Italy who were receiving THC:CBD oromucosal spray and had associated oral mucosal effects were randomized into Group A (chewing gum; n = 15); Group B (cold bottle; n = 20); and Group C (cold bottle + chewing gum; n = 17).
Taste perception in patients receiving chewing gum ± cold bottle intervention (Groups A and C combined) was significantly (p = 0.0001) improved from baseline to week 4 while maintaining spasticity control.
Patient comfort, satisfaction and treatment adherence may benefit from these interventions.
关于Δ-四氢大麻酚（THC）：大麻二酚（CBD）口腔黏膜喷雾剂（Sativex；英国索尔兹伯里GW制药有限公司）用于治疗多发性硬化症痉挛的投诉包括味道不佳和口腔黏膜异常。这项前瞻性研究评估了使用无糖口香糖和/或冷藏的THC：CBD口腔黏膜喷雾剂来减轻这些影响。
在意大利六个地点接受THC：CBD口腔黏膜喷雾剂且有相关口腔黏膜影响的多发性硬化症痉挛患者（n = 52）被随机分为A组（口香糖；n = 15）；B组（冷藏瓶；n = 20）；C组（冷藏瓶 + 口香糖；n = 17）。
接受口香糖±冷藏瓶干预的患者（A组和C组合并）从基线到第4周的味觉感知显著（p = 0.0001）改善，同时维持痉挛控制。
这些干预措施可能有益于患者舒适度、满意度和治疗依从性。
Zotero 插件